Key facts
- It has raised $24.7M; the latest was Later Stage VC ($15.8M) in Mar 2026.
- Notable investors include Tech Incubator Program for Startup, Korea Development Bank, FuturePlay, Korea Technology Finance, Posco Investment — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for DewCell
- ·The full record, as it builds
Funding rounds
No funding rounds for DewCell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DewCell
Developer of a biotechnology company designed to create artificial platelets using human-derived stem cell-induced differentiation technology and biomimetic technology. The company's system secures differentiation technology from stem cells into megakaryocytes that generate platelets and mass-produces artificial platelets, providing medical researchers with platelets that can solve the shortage of blood-derived platelets.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2021
- Employees
- 25
- Website
- dewcell.com/
- Ownership
- Privately Held (backing)
DewCell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DewCell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DewCell in its N-PORT filings yet. We sweep new filings monthly.